Antibody-Drug – Talk Bio

DualityBio Pursues $200M IPO in Hong Kong Amid Volatile Market Conditions

2 weeks ago talkbio0Tagged Antibody-Drug, BioNTech, biotech sector, DualityBio, global trade tensions, Hong, Immunostimulating conjugate (antigen), Investments, IPO, Kong, Market, Stock exchange, upheaval

DualityBio, IPO, Hong Kong Stock Exchange, biotech investment, antibody-drug conjugates, BioNTech, market upheaval, global trade tensions, biotech sector growth.

ImmunoPrecise Antibodies Secures $8-10M Partnership for Novel Cancer Therapeutics Development

1 month ago talkbio0Tagged Antibodies, Bispecific, Antibody-Drug, Antibody-Drug Conjugates, B-cell Select ™ technology, Cancer Therapeutic Procedure, Discover, ImmunoPrecise Antibodies, Immunostimulating conjugate (antigen)

ImmunoPrecise Antibodies, Antibody-Drug Conjugates (ADCs), bispecific antibodies, cancer treatment, AI-driven discovery, B-cell Select™ technology

Callio Therapeutics Debuts with $187M to Develop Next-Generation Multi-Payload ADCs for Cancer

2 months ago talkbio0Tagged ADCs, Antibody-Drug, Biotechnology, Cancer Therapeutic Procedure, dual-payload technology, HER2-targeted therapy, Immunostimulating conjugate (antigen), multi-payload, Neoplasms

Multi-payload ADCs, antibody-drug conjugates, oncology, HER2-targeted therapy, dual-payload technology, cancer treatment, biotechnology startup

Pfizer and Summit Therapeutics Collaborate on Innovative Cancer Therapy Combinations

2 months ago talkbio0Tagged Antibodies, Bispecific, Antibody-Drug, Antibody-Drug Conjugates, Clinical Trials, Ivonescimab, PD-1/VEGF, Pfizer, Solid Neoplasm, summit

Pfizer, Summit Therapeutics, ivonescimab, antibody-drug conjugates (ADCs), PD-1/VEGF bispecific antibody, solid tumors, clinical trials

Daiichi Sankyo Expands Cancer Research and Manufacturing Capacity in Germany

3 months ago talkbio0Tagged Antibody-Drug, Antibody-Drug Conjugates, Cancer Research, Capacity, Daiichi, Germany, innovation, Manufacturing, Pfaffenhofen facility, Sankyo

Daiichi Sankyo, antibody-drug conjugates (ADCs), cancer research, manufacturing capacity, Germany, Pfaffenhofen facility, innovation center

Pfizer and PostEra Expand AI-Driven Drug Discovery Partnership to Include Antibody-Drug Conjugates (ADCs)

4 months ago talkbio0Tagged Antibody-Drug, Antibody-Drug Conjugates, Aortic Valve Insufficiency, Chemistry, Pharmaceutical, Drug Discovery, Immunostimulating conjugate (antigen), Laboratory, Pfizer, Pfizer/, PostEra, Proton Platform, Small Molecule

AI-driven drug discovery, Antibody-Drug Conjugates (ADCs), Pfizer, PostEra, AI Lab, Proton platform, small molecule therapeutics, medicinal chemistry.